Self assembled precusor liposome containing hard soluble medicine and its preparation method

A technology of proliposomes and insoluble drugs, applied in liposome delivery, medical preparations of non-active ingredients, pharmaceutical formulations, etc., can solve incomplete local dissolution and decreased encapsulation efficiency of drug-containing liposomes , drug encapsulation rate reduction and other issues, to achieve the effect of solving high-efficiency industrial production, safe and easy to purchase, stable and controllable quality

Inactive Publication Date: 2006-08-30
CHINA PHARM UNIV
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] 1. The preparation process is complicated, prone to bacterial contamination, poor reproducibility, difficult to industrialized large-scale production, and high manufacturing cost
[0007] 2. Poor preparation quality stability
[0009] (2) During storage of drug-containing liposome liquid preparations, there are objectively: the phenomenon of drug diffusion (or leakage) from liposomes to the liquid medium, resulting in reduced or unstable drug encapsulation efficiency; (or aggregation) tendency, also causes the important factor that liposome average particle size becomes larger or unstable
[0010] (3) During the dissolution and dispersion process of drug-containing liposome solid (lyophilized) preparations before use, liposome aggregation or average particle size becomes larger due to incomplete local dissolution and uneven dispersion of liposome nanoparticles ; or liposome rupture, drug leakage, resulting in decreased encapsulation efficiency of drug-containing liposomes
In view of the fact that in the process of preparing solid proliposomes, the process of removing organic solvents is the main technical bottleneck to realize industrialization, and the hydration process of solid proliposomes will also objectively have a slow hydration rate and incomplete local dissolution , uneven dispersion and other problems, which makes it difficult to effectively control the main quality indicators such as drug encapsulation rate and average particle size
[0014] In the existing published patents, research literature and reports on the preparation of liposomes and proliposomes, no preparation technology directly using liquid self-assembled proliposomes has been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Self assembled precusor liposome containing hard soluble medicine and its preparation method
  • Self assembled precusor liposome containing hard soluble medicine and its preparation method
  • Self assembled precusor liposome containing hard soluble medicine and its preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] prescription:

[0068] Paclitaxel 0.6g

[0069] Soy Lecithin 37.5g

[0070] Polyoxyethylene hydrogenated castor oil (Cremophor RH40) 18.75g

[0071] Cholesterol 2.5g

[0072] Ethanol to 100ml

[0073] Preparation process: according to figure 1 The process flow chart shown dissolves the prescribed amount of soybean lecithin in an appropriate amount of ethanol, and then adds the prescribed amount of medicine, polyoxyethylene hydrogenated castor oil Cremophor RH40, cholesterol and the remaining amount of ethanol, after the medicine and other components are completely dissolved , 0.22μm microporous membrane filtration sterilization, under sterile conditions, the filtrate can be sealed in nitrogen-filled ampoules or vials.

[0074] Adding the prepared paclitaxel self-assembled proliposomes to 50 times the amount (v / v) of 5% glucose injection can quickly form a paclitaxel liposome solution with an average particle size of 95 %.

Embodiment 2

[0076] Prescription: Nimodipine 1.0g

[0077] Egg phospholipids 16.7g

[0078] Tween 80 10.7g

[0079]Polyoxyethylene castor oil (Cremophor EL) 6.0g

[0080] Ethanol up to 50ml

[0081] Preparation process: dissolve the prescribed amount of egg phospholipids in an appropriate amount of ethanol, then add the prescribed amount of nimodipine, Tween 80, polyoxyethylene castor oil Cremophor EL and the remaining amount of ethanol, and wait until the drug and other components are completely dispersed Or after dissolving, filter and sterilize with a 0.22 μm microporous membrane, fill and seal the filtrate in a nitrogen-filled ampoule under aseptic conditions to obtain the nimodipine self-assembled proliposome.

[0082] After adding the prepared nimodipine self-assembled proliposome to 100 times the amount (v / v) of glucose sodium chloride solution, the nimodipine liposome solution can be formed rapidly, with an average particle diameter 90%.

Embodiment 3

[0084] Prescription: Curcuma Oil 1ml

[0085] Soy Lecithin 10g

[0086] Polyoxyethylene hydrogenated castor oil (Cremophor RH60) 3.7g

[0087] Ethanol to 25ml

[0088] Preparation process: dissolve the prescribed amount of soybean lecithin in an appropriate amount of ethanol, then add the prescribed amount of zedoary oil, polyoxyethylene hydrogenated castor oil Cremophor RH60 and the remaining amount of ethanol, after the drug and other components are completely dispersed or dissolved, The 0.22 μm microporous membrane was filtered and sterilized, and the filtrate was filled and sealed in a nitrogen-filled ampoule under aseptic conditions to obtain the self-assembled proliposome of zedoary oil.

[0089] The prepared zedoary oil self-assembled proliposome is added to 25 times the amount (v / v) of physiological saline, and the zedoary oil liposome solution can be rapidly formed, with an average particle size of 90%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to view more

Abstract

A self-assembled precursor liposome of medicine difficult to dissolve is proportionally prepared from medicine difficult to dissolve, phosphatide, polyethylene glycol and dispersing medium through mixing, dispersing, press filtering by millipore film, and pouring it in a container full of N2.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and relates to a self-assembled proliposome containing insoluble drugs, and also relates to a preparation method of the self-assembled proliposome. Background technique [0002] Liposomes (liposomes, also known as lipid globules) are bilayer microvesicles that resemble biological membrane structures. In 1971, British Rymen et al began to use liposomes as drug carriers. [0003] Liposome is a nanoscale particle containing phospholipid components, which can be used as a carrier for insoluble and water-soluble drugs, and is a new type of pharmaceutical preparation. After the drug-containing liposome is administered intravenously, it is mainly swallowed by the reticuloendothelial system, so that the drug is mainly accumulated in tissues and organs such as the liver, spleen, lung and bone marrow, and the distribution of the encapsulated drug in the body is changed, thereby improving the the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/127A61K47/24A61K47/34A61K47/10
Inventor 周建平仝新勇谭燕
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products